Fluconazol e própolis co-encapsulados em nanopartículas mucoadesivas para o tratamento da candidíase vulvovaginal

Abstract

Vulvovaginal Candidiasis is the second most common infection in women of childbearing age, in about 70 to 90% of cases; the associated etiologic agent is C. albicans. The increase in the incidence of non-albicans species has led to the emergence of cases of resistance to antifungals, which is why the importance of new approaches in treatment. The objective of the present work was to develop and test in vivo a nanostructured system containing fluconazole and Green Propolis for the treatment of Vulvovaginal Candidiasis. The nanoparticles containing Fluconazole and Green Propolis were prepared following the technique of ionic gelation and presented satisfactory physical characteristics for the intended purpose. The association efficiency for the complexed compounds was performed using the technique of High Performance Liquid Chromatography (HPLC) and UV spectrophotometry. The Minimum Inhibitory Concentrations (MIC) for Fluconazole, Green Propolis and nanoparticles were determined, showing efficacy for use and fungistatic action on C. albicans ATCC 10231. Release analyzes of up to 72 hours with stabilization up to 96 hours were verified in the nanoparticles. The toxicity tests by hemolysis and Galleria mellonella, demonstrated positive results for propolis and negative for nanoparticles, suggesting safety in their use in a method with a murine model. In vivo tests were performed with an indication of efficacy for the proposed formulation.